Greenwich LifeSciences, Inc. announced that The Food and Drug Administration (the FDA") reviewed the Company's Phase IIb clinical data before the commencement of the Flamingo-01 clinical trial. The first US sites were activated in the 3 Quarter of 2022 and the clinical trial is currently enrolling patients and has been screening and treating patients since the 4 Quarter of 2022. DTH skin tests are being conducted and blood samples are being collected to assess immune response.

The Company is planning an expansion of the Flamedo-01 clinical trial into Europe. The abstract and poster at the upcoming AACR conference, scheduled for the Phase II and Phase III Clinical Trials in Progress poster session on April 17, 2023, is focused only on the design of Flamingo-01 and is intended for discussions with clinicians.